Mike Israetel on retatrutide: what the bodybuilding coach says about the experimental triple agonist, muscle loss, dosing, and availability.
Mike Israetel has talked about retatrutide the way he talks about most new weight-loss drugs: as a powerful tool that still has to be paired with hard resistance training and high protein intake if you want to keep your muscle. Israetel is a PhD exercise scientist and bodybuilding coach, not a physician or drug developer, so his view comes from reading trial data through a physique lens rather than from running his own studies. He has not endorsed retatrutide, and he does not prescribe it.
Who Mike Israetel Is and Why His Opinion Carries Weight
Israetel holds a doctorate in sport physiology and co-founded Renaissance Periodization, a coaching and education company built around hypertrophy and contest prep. He has coached physique athletes and produces a large volume of YouTube and podcast content on dieting, training volume, and body composition.
That background explains why the fitness world wants to know what he thinks about retatrutide. Most retatrutide coverage focuses on scale weight, while Israetel's audience cares about how much of that weight is fat and how much is muscle.
Scope matters here. Israetel is not an endocrinologist and is not connected to the retatrutide clinical program. His commentary is expert interpretation, not primary research.
What Mike Israetel Has Said About Retatrutide
In podcasts and video breakdowns, Israetel has discussed retatrutide alongside semaglutide and tirzepatide. A few themes come up again and again.
- The weight-loss numbers are impressive. In a phase 2 trial, participants on the highest dose lost roughly 24% of body weight over 48 weeks on average, which is a larger result than approved drugs produced in their own trials.
- It is still experimental. Retatrutide has not been approved by the FDA, and phase 3 data are still being collected.
- Muscle loss is the central risk. Rapid weight loss of any kind pulls some lean tissue with it, and faster loss tends to mean more of it.
- Training and protein are the countermeasure. His standard advice is heavy resistance training several times per week plus protein at roughly 0.7 to 1 gram per pound of body weight.
- Appetite suppression can backfire. When hunger drops sharply, people often under-eat protein and skip workouts, which is how a physique-focused diet goes wrong.
The glucagon receptor component of retatrutide also gets attention in his commentary, because it may raise energy expenditure in addition to reducing appetite. That mechanism is one reason researchers treat the triple agonist as different from a plain GLP-1 drug.
Why Muscle Retention Is the Center of the Debate
Lean mass can make up a meaningful share of total weight lost on GLP-1 class drugs, with commonly cited figures between 20% and 40% depending on the study and the measurement method. Losing that tissue lowers resting energy expenditure and can leave someone smaller but softer at the same body fat percentage.
Israetel's argument is that this outcome is partly avoidable. Resistance training, adequate protein, and a moderate rate of loss preserve far more lean tissue than a crash diet with no training, whether or not a drug is involved.
For bodybuilders the concern is competitive as well as aesthetic. A drug that produces fast fat loss but flattens training performance is a poor trade during a growth phase or a contest prep.
Retatrutide Compared With Other Weight-Loss Drugs
Retatrutide is a triple agonist, meaning it targets three hormone receptors instead of one or two. That difference shows up in how researchers compare it with other options.
| Drug | Receptors targeted | US status | Average weight loss in trials |
|---|---|---|---|
| Semaglutide (Wegovy) | GLP-1 | FDA-approved | About 15% |
| Tirzepatide (Zepbound) | GIP and GLP-1 | FDA-approved | About 21% |
| Retatrutide | GIP, GLP-1 and glucagon | Investigational (phase 3) | About 24% at 48 weeks |
| Cagrilintide plus semaglutide | Amylin analog plus GLP-1 | Investigational | About 23% at 68 weeks |
When people compare cagrilintide vs retatrutide vs tirzepatide, the honest answer is that only tirzepatide is approved for human use in the United States today. The other two remain experimental, and cross-trial comparisons are rough because the studies used different populations, durations, and dosing schedules.
Dosing, Approval, and the Online Gray Market
Questions about retatrutide dosage come up constantly, but there is no approved dose for humans. The phase 2 trial used once-weekly injections from 1 mg up to 12 mg with slow titration, and those numbers describe a research protocol rather than a recommendation for anyone.
The question of when will retatrutide be available cannot be answered with certainty. Eli Lilly is running the TRIUMPH phase 3 program, and if the data hold up, a regulatory decision could arrive around 2026 or 2027.
Search demand for where to buy retatrutide is high, and that is exactly where the risk lives. Powder sold online as a "research chemical" is not approved for human use, is not legally sold as a drug, and carries no guarantee of purity, sterility, or actual dose. Sites offering compound retatrutide are on equally shaky ground, because retatrutide is not an approved drug and therefore has no lawful compounding pathway for patient use.
Anyone considering a GLP-1 drug should talk with a healthcare professional and stick to approved products. Unregulated peptides have caused serious injection-site reactions, infections, and hospitalizations in reported cases.
What the Physique Playbook Says to Do Instead
Israetel's practical guidance for someone using any weight-loss drug is the same advice he gives for any aggressive diet:
- Train with weights three to five times per week, close to failure on major lifts.
- Keep protein high, around 0.7 to 1 gram per pound of body weight daily.
- Aim for a moderate deficit rather than the fastest possible drop.
- Track strength and measurements, not just scale weight.
That approach protects lean mass no matter which drug eventually wins approval. It also keeps results in place if the medication is later stopped.
Bottom Line on Mike Israetel and Retatrutide
Mike Israetel treats retatrutide as a promising but unapproved drug whose main practical downside is muscle loss during rapid weight reduction. Retatrutide is not FDA-approved for human use in the United States and remains in phase 3 trials. Israetel's core message is that drugs do not replace resistance training and adequate protein, and that anyone using a GLP-1 medication should do so under medical supervision.
Reports of retatrutide's phase 2 results are the strongest argument for the drug so far, and they are still not a substitute for phase 3 safety data or an approved label.
Frequently Asked Questions
Has Mike Israetel recommended retatrutide?
No. Israetel has discussed retatrutide in podcasts and videos as an investigational drug with strong early weight-loss data, but he has not recommended it and does not prescribe it. His emphasis is on pairing any weight-loss drug with resistance training and high protein intake to protect muscle.
Is retatrutide available in the United States?
No. Retatrutide is not FDA-approved and is still in phase 3 trials, so it cannot legally be sold or prescribed for human use in the US. Products marketed online as retatrutide are unapproved research chemicals with no guaranteed purity, sterility, or dosing accuracy.
What dosage of retatrutide was studied in trials?
The phase 2 trial tested once-weekly doses from 1 mg up to 12 mg with gradual titration over several weeks. Those figures describe a research protocol and are not a dosing recommendation for anyone. Someone considering a GLP-1 medication should speak with a healthcare professional.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.